Renal safety in patients treated with bisphosphonates for osteoporosis: A review

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Using Proteinuria and Estimated Glomerular Filtration Rate to Classify Risk in Patients With Chronic Kidney Disease

(2013) Marcello Tonelli   ANNALS OF INTERNAL MEDICINE

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

PTH--A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?

(2012) G. Garrett et al.   Clinical Journal of the American Society of Nephrology

BMD and Fracture Risk in CKD: Where Should We Go from Here?

(2012) T. L. Nickolas   Clinical Journal of the American Society of Nephrology

Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

(2012) Sundeep Khosla et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Osteoporosis and adynamic bone in chronic kidney disease

(2012) Jorge B. Cannata-Andía et al.   JOURNAL OF NEPHROLOGY

Oral bisphosphonate use in the elderly is not associated with acute kidney injury

(2012) Andrew W.Y. Shih et al.   KIDNEY INTERNATIONAL

Arterial calcification and bone physiology: role of the bone–vascular axis

(2012) Bithika Thompson et al.   Nature Reviews Endocrinology

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

(2012) Steven Boonen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparing the association of GFR estimated by the CKD-EPI and MDRD study equations and mortality: the third national health and nutrition examination survey (NHANES III)

(2012) Tariq Shafi et al.   BMC Nephrology

Bone and Kidney Disease: Diagnostic and Therapeutic Implications

(2012) Sophie A. Jamal et al.   Current Rheumatology Reports

Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP)

(2011) Lesley A. Stevens et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease — The DIVINE study

(2011) Paul D. Miller et al.   BONE

Bisphosphonates: The first 40years

(2011) R. Graham G. Russell   BONE

The kidney and bisphosphonates

(2011) Paul D. Miller   BONE

Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease

(2011) Tamara Isakova   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure

(2011) Navdeep Tangri   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Discriminants of Prevalent Fractures in Chronic Kidney Disease

(2011) T. L. Nickolas et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

(2011) Tamara Isakova et al.   KIDNEY INTERNATIONAL

Fracture risk assessment in patients with chronic kidney disease

(2011) S. A. Jamal et al.   OSTEOPOROSIS INTERNATIONAL

Renal Insufficiency and Failure

(2011) M. A. Dimopoulos et al.   Hematology-American Society of Hematology Education Program

Cancer and renal insufficiency results of the BIRMA study

(2010) N Janus et al.   BRITISH JOURNAL OF CANCER

FGF-23: More than a regulator of renal phosphate handling?

(2010) Harald Jüppner et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Chronic Kidney Disease in Older People: Physiology, Pathology or Both?

(2010) Ahmed H. Abdelhafiz et al.   NEPHRON CLINICAL PRACTICE

Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study

(2010) P. N. Sambrook et al.   OSTEOPOROSIS INTERNATIONAL

Fragility fractures in chronic kidney disease: An opinion-based approach

(2009) P. D. MILLER   CLEVELAND CLINIC JOURNAL OF MEDICINE

Adynamic bone disease: clinical and therapeutic implications

(2009) João M Frazão et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

High Prevalence of Stage 3 Chronic Kidney Disease in Older Adults Despite Normal Serum Creatinine

(2008) O. Kenrik Duru et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

(2008) Steven Boonen et al.   KIDNEY INTERNATIONAL

Bisphosphonate nephrotoxicity

(2008) Mark A. Perazella et al.   KIDNEY INTERNATIONAL

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy

(2008) R. G. G. Russell et al.   OSTEOPOROSIS INTERNATIONAL

Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety

(2008) Anke Lühe et al.   TOXICOLOGY IN VITRO

Renal Toxicity following Zoledronic Acid Reversed with Ibandronate in a Prostate Cancer Patient with Bone Metastases

(2008) Timo K. Joensuu   UROLOGIA INTERNATIONALIS